Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience

IntroductionReal-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Klebsiella pneumoniae complex (KPC-Kp) and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa (DTR-PA) infections is herein described.MethodsAdult patients with KPC-Kp or DTR-PA...

Full description

Bibliographic Details

Published in:	Frontiers in Microbiology
Main Authors:	Cristiana Leanza, Maria Teresa Mascellino, Lorenzo Volpicelli, Sara Covino, Antonio Falletta, Francesca Cancelli, Cristiana Franchi, Martina Carnevalini, Claudio M. Mastroianni, Alessandra Oliva
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	imipenem-relebactam KPC-producing Klebsiella pneumoniae imipenem/cilastatin/relebactam ceftazidime-avibactam resistance polymicrobial infections antimicrobial resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2024.1432296/full